Form Type: 4

SEC EDGAR Link
Acccession Number:0001209191-19-045822
Date:2019-08-13
Issuer: DECIPHERA PHARMACEUTICALS, INC. (DCPH)
Original Submission Date:

Reporting Person:

TAYLOR MICHAEL DOUGLAS
C/O DECIPHERA PHARMACEUTICALS, INC.
500 TOTTEN POND ROAD WALTHAM, MA 02451

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2019-08-13 M 22,500 a $1.89 22,500 direct
COMMON STOCK 2019-08-13 S 3,433 d $39.47 19,067 direct
COMMON STOCK 2019-08-13 S 13,767 d $40.50 5,300 direct
COMMON STOCK 2019-08-13 S 1,300 d $41.77 4,000 direct
COMMON STOCK 2019-08-13 S 4,000 d $42.49 0 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
STOCK OPTION (RIGHT TO BUY) 1.89 2019-08-13 deemed execution date M 22,500 (d) 2025-12-17 common stock 22,500 $1.89 517,135 direct
Footnotes
IDfootnote
f1 the sales reported in this form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person.
f2 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $39.10 to $40.03, inclusive. the reporting person undertakes to provide to deciphera pharmaceuticals, inc., any security holder of deciphera pharmaceuticals, inc., or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
f3 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $40.14 to $41.10, inclusive. the reporting person undertakes to provide to deciphera pharmaceuticals, inc., any security holder of deciphera pharmaceuticals, inc., or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
f4 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $41.22 to $42.13, inclusive. the reporting person undertakes to provide to deciphera pharmaceuticals, inc., any security holder of deciphera pharmaceuticals, inc., or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
f5 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $42.27 to $42.90, inclusive. the reporting person undertakes to provide to deciphera pharmaceuticals, inc., any security holder of deciphera pharmaceuticals, inc., or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
f6 this stock option award was issued pursuant to deciphera pharmaceuticals, llc's 2015 equity incentive plan. the option vests in 16 equal quarterly installments at the end of each quarter following the vesting commencement date of march 1, 2014, subject to continued service through such dates.

Elevate your investments